279279
Estatinas e outros antidislipidémicos
44. Fellström BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and car-
diovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407.
45. Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL
cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study
of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 37:
2181-92.
46. O´Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl.
Lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142-6.
47. Armitage J.The safety of statins in clinical practice. Lancet. 2007; 370: 1781-90.
48. Silva PM. Terapêutica redutora intensiva do colesterol: a certeza da segurança. Rev Port
Cardiol 2010; 29: 1405-18.
49. Zhang H, Plutzky J, Skentzos S, et al Discontinuation of statins in routine care settings: a
cohort study. Ann Intern Med. 2013; 158: 526-34.
50. Stulc T, Ceška R, Gotto AM Jr. Statin intolerance: the clinician’s perspective. Curr Atheros-
cler Rep. 2015; 17: 69.
51. Patel J, Superko HR, Martin SS, et al. Genetic and immunologic susceptibility to statin-related
myopathy. Atherosclerosis. 2015; 240: 260-71.
52. Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to eviden-
ce-based solutions. Curr Opin Lipidol. 2015; 26: 221-7.
53. Magni P, Macchi C, Morlotti B, et al. Risk identification and possible countermeasures for
muscle adverse effects during statin therapy. Eur J Intern Med. 2015; 26: 82-8.
54. Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association’s Muscle Safety
Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin
Lipidol. 2014; 8 (3 Suppl): S58-71.
55. Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myoto-
xicity. Clin Pharmacol Ther. 2014; 96: 470-6.
56. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes
mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014; 15: 1-15.
57. Silva PM. Temos uma sustentação biológica para a diabetes associada às estatinas?
[comentário). Rev Port Cardiol. 2015; 34: 435-8.
58. DeMicco DA, Barter P, Cannon CP, et al. Risk of incident diabetes with intensive-dose com-
pared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305: 2556-64.
59. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. . HMG-coenzyme A reductase inhibition,
type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lan-
cet. 2015; 385: 351-61.
60. Besseling J, Kastelein JJ, Defesche JC, et al. Association between familial hypercholesterole-
mia and prevalence of type 2 diabetes mellitus. JAMA. 2015; 313: 1029-36.
61. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Canadian Network for Observational
Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney
injury: multicenter, retrospective observational analysis of administrative databases. BMJ.
2013; 346: f880.
